Reasons for Failure and Relapse and Mechanism...

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent ther ...  Show more

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should of ...  Show more

In Part 1 of this pair of episodes, Drs. Rita Dib and Joseph Sassine provide a background of CAR-T cell therapy (chimeric antigen receptor T cells) and steer you through the complications that might contribute to fever early after CAR-T.Episodes | Consult Notes | Subscribe | Twit ...  Show more

In Part 2 of this pair of episodes, Drs. Rita Dib and Joseph Sassine zoom through the late infectious complications of CAR-T cell therapy.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com 

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.
  
Credit available for this activity expires: 07/31/25
Earn Credit / Learning Obje ...